150 S Saunder Road
About Horizon Pharma
At Horizon Pharma, we are focused on improving patients' lives by developing, acquiring, commercializing and delivering breakthrough medicines to patients because we understand the challenges they face. We market 11 medicines that address unmet treatment needs for rare and rheumatic diseases. By leading research for medicines in development, exploring all potential uses for medicines and ensuring access to medicines prescribed, we can make a powerful difference for our patients, their caregivers and physicians. The outcomes we attain – and the lengths we go to achieve them – reflect our company ideals, a commitment to our patients and the communities we serve. For us, it's personal: by living up to our own potential, we are helping others live up to theirs.
Stock symbol: HZNP
At Horizon, we work to define ourselves by a different set of numbers - the number of patients helped, lives changed, lives saved. In this video, hear from our employees on why working at Horizon Pharma is personal.
331 articles with Horizon Pharma
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences
Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
Quarterly Net Sales Increased 20 Percent to $325.3 Million, a Record for the Company; Third-Quarter 2018 GAAP Net Income of $26.0 Million; Adjusted EBITDA of $149.9 Million
Horizon Pharma plc (Nasdaq: HZNP) has been awarded a 2018 Top Workplaces honor by the Chicago Tribune.
Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
Horizon Pharma plc announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the American Academy of Ophthalmology (AAO) Annual Meeting, Oct. 27 – 30, 2018, in Chicago, Ill.
A replay of the webcast will be available for each event.
Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout.
Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
Horizon to also host onsite discussion with prominent researchers on pathophysiology of gout
FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
The Best Small & Medium Workplaces list is one of a series of rankings by Great Place to Work and FORTUNE based on employee feedback from Great Place to Work-Certified™ organizations.
Horizon Pharma (Nasdaq: HZNP) announced today that its third-quarter financial results will be released on Wednesday, Nov. 7, 2018.
Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24 maintained these reductions 48 weeks following the study completion, or nearly a year off therapy.
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
Topline results expected in second quarter of 2019
Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases
-- Record Quarterly Orphan and Rheumatology Segment Net Sales of $201.7 Million Increased 17 Percent; Represented 67 Percent of Total Company Net Sales --
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
Horizon Pharma also formally commits to become a Pledge 1% company
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Will Represent the Tenth and Eleventh U.S. Patents to be Listed in the Orange Book for RAVICTI
Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018
Horizon Pharma plc announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to thi...